Your browser doesn't support javascript.
loading
Optimal short-term outcomes in balloon pulmonary angioplasty: the minimum frequency of three sessions annually.
Li, Xin; Yang, Tao; Zhang, Yi; Zhao, Qing; Zeng, Qixian; Jin, Qi; Duan, Anqi; Huang, Zhihua; Hu, Meixi; Zhang, Sicheng; Gao, Luyang; Xiong, Changming; Luo, Qin; Zhao, Zhihui; Liu, Zhihong.
Afiliación
  • Li X; Center for Respiratory and Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China.
  • Yang T; Center for Respiratory and Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China.
  • Zhang Y; Center for Respiratory and Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China.
  • Zhao Q; Department of ICU, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
  • Zeng Q; Center for Respiratory and Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China.
  • Jin Q; Center for Respiratory and Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China.
  • Duan A; Center for Respiratory and Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China.
  • Huang Z; Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Hu M; Center for Respiratory and Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China.
  • Zhang S; Center for Respiratory and Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China.
  • Gao L; Center for Respiratory and Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China.
  • Xiong C; Center for Respiratory and Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China.
  • Luo Q; Center for Respiratory and Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China.
  • Zhao Z; Center for Respiratory and Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China.
  • Liu Z; Center for Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, No.167 Beilishi Road, Xicheng District, Beijing 100037, China.
Ther Adv Respir Dis ; 18: 17534666241232521, 2024.
Article en En | MEDLINE | ID: mdl-38409856
ABSTRACT

BACKGROUND:

Balloon pulmonary angioplasty (BPA) is typically performed in a sequential manner.

OBJECTIVES:

This study aimed to determine the lowest frequency of BPA for patients who could not reach treatment goals in a short period.

DESIGN:

Retrospective cohort.

METHODS:

We retrospectively enrolled 186 BPA-treated patients diagnosed with chronic thromboembolic pulmonary hypertension. According to the accumulative number of performed BPA sessions or treated pulmonary vessels or the ratio of the number of treated pulmonary vessels/the number of baseline lesions (T/P) prior to the initial occurrence of clinical outcome or censored date, we divided patients into different groups. The principal outcome was clinical worsening.

RESULTS:

After stratifying patients by the number of performed BPA sessions, most baseline parameters were comparable among groups. During follow-up, 31 (16.7%) of 186 patients experienced clinical worsening. The 6-month cumulative clinical worsening-free survival rates of ⩾2 performed sessions group were significantly higher than that of 1 performed session group. The 12-month cumulative rates of clinical worsening-free survival exhibited a declining pattern in the subsequent sequence ⩾3, 2, and 1 performed BPA sessions, and this trend persisted when follow-up time exceeded 12 months. The 6-, 12-, and 24-month cumulative clinical worsening-free survival rates were comparable between patients with 3 and ⩾4 performed BPA sessions. Similar results were also observed when stratifying patients by the accumulative number of treated pulmonary vessels (⩽8, 9-16, ⩾17) and T/P (⩽0.789, 0.790-1.263, ⩾1.264).

CONCLUSION:

To achieve optimal short-term outcomes, patients might need to undergo ⩾2 BPA sessions or have ⩾9 pulmonary vessels treated or have T/P ⩾0.790 within 6 months, and undergo ⩾3 BPA sessions or have ⩾17 pulmonary vessels treated or have T/P ⩾1.264 within 12 months.
The least number of BPA session to reach a favorable outcomeWhy was the study done? Balloon pulmonary angioplasty (BPA) has been recommended for patients with chronic thromboembolic pulmonary hypertension, which can significantly improve patients' hemodynamics. However, BPA is typically performed in a stepwise manner, and the duration from the initial session to the final session could extend over a year. If patients could not quickly undergo adequate number of BPA sessions and reach hemodynamic target due to various reasons, what is the best frequency of BPA for them? What did the researchers do? We retrospectively enrolled 186 BPA-treated patients diagnosed with chronic thromboembolic pulmonary hypertension. According to the accumulative number of BPA sessions, we divided patients into different groups to identify the best frequency of BPA to improve prognosis. What did the researchers find? Patients who received at least two BPA sessions within six months had significantly better prognosis than those with one BPA session. Patients who received at least three BPA sessions within a year had significantly better prognosis than those with two BPA sessions. What do the findings mean? To achieve optimal short-term outcome, patients might need to undergo at least two BPA sessions within six months, and undergo at least three BPA sessions within a year.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Embolia Pulmonar / Angioplastia de Balón Límite: Humans Idioma: En Revista: Ther Adv Respir Dis Asunto de la revista: PNEUMOLOGIA / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Embolia Pulmonar / Angioplastia de Balón Límite: Humans Idioma: En Revista: Ther Adv Respir Dis Asunto de la revista: PNEUMOLOGIA / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: China